NASDAQ:HOWL

Werewolf Therapeutics (HOWL) Stock Forecast, Price & News

$3.38

-0.09 (-2.59%)

(As of 06/7/2023 ET)

Compare

Today's Range: $3.38
▼
$3.67
50-Day Range: $2.31
▼
$3.65
52-Week Range: $1.39
▼
$7.51

Volume: 46,930 shs
Average Volume: 35,227 shs
Market Capitalization: $120.36 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.10

Werewolf Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 228.4% Upside
$11.10 Price Target
Short Interest: Healthy
0.23% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.46
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.32) to ($1.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

349th out of 981 stocks

Pharmaceutical Preparations Industry

163rd out of 485 stocks

3.5

Analyst's Opinion

Consensus Rating
Werewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.10, Werewolf Therapeutics has a forecasted upside of 228.4% from its current price of $3.38.
Amount of Analyst Coverage
Werewolf Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.23% of the float of Werewolf Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Werewolf Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Werewolf Therapeutics does not currently pay a dividend.
Dividend Growth
Werewolf Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HOWL.

1.4

News and Social Media Coverage

News Sentiment
Werewolf Therapeutics has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.
Search Interest
4 people have searched for HOWL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
62.70% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
68.17% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.32) to ($1.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Werewolf Therapeutics is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Werewolf Therapeutics is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Werewolf Therapeutics has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Stock News Headlines

June 6, 2023 | msn.com

Werewolf assumed Buy at Jefferies ahead of data for key cancer drug

June 1, 2023 | finance.yahoo.com

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

June 8, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 16, 2023 | americanbankingnews.com

Financial Survey: Werewolf Therapeutics (NASDAQ:HOWL) and Onconova Therapeutics (NASDAQ:ONTX)

May 16, 2023 | americanbankingnews.com

Werewolf Therapeutics (NASDAQ:HOWL) PT Raised to $10.00

May 15, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on Werewolf Therapeutics (HOWL)

May 13, 2023 | msn.com

B of A Securities Maintains Werewolf Therapeutics (HOWL) Buy Recommendation

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Werewolf Therapeutics (HOWL) Buy Recommendation

June 8, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 12, 2023 | markets.businessinsider.com

Bank of America Securities Keeps Their Buy Rating on Werewolf Therapeutics (HOWL)

May 11, 2023 | msn.com

Recap: Werewolf Therapeutics Q1 Earnings

May 11, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Werewolf Therapeutics (HOWL)

May 11, 2023 | markets.businessinsider.com

Expert Ratings for Werewolf Therapeutics

May 11, 2023 | finance.yahoo.com

Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates

May 11, 2023 | finance.yahoo.com

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023 | finance.yahoo.com

Werewolf Therapeutics to Participate in May Investor Conferences

April 24, 2023 | news.yahoo.com

‘Stunning’ Wolf Discovery Caught On Wildlife Camera In Minnesota

April 20, 2023 | marketwatch.com

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE(TM) Molecule, in Cancer Immunology Research

April 19, 2023 | finanznachrichten.de

Werewolf Therapeutics, Inc.: Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE Molecule, in Cancer Immunology Research

April 19, 2023 | technews.tmcnet.com

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

April 19, 2023 | finance.yahoo.com

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

March 29, 2023 | americanbankingnews.com

Analysts Set Expectations for Werewolf Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:HOWL)

March 28, 2023 | markets.businessinsider.com

SVB Securities Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)

March 27, 2023 | americanbankingnews.com

Werewolf Therapeutics (NASDAQ:HOWL) Earns Buy Rating from EF Hutton Acquisition Co. I

March 24, 2023 | msn.com

Werewolf Therapeutics Earnings Perspective: Return On Capital Employed

March 24, 2023 | markets.businessinsider.com

Analyst Ratings for Werewolf Therapeutics

March 24, 2023 | americanbankingnews.com

Werewolf Therapeutics (NASDAQ:HOWL) PT Lowered to $15.00

See More Headlines

HOWL Price History

30 days | 90 days | 365 days | Advanced Chart

HOWL Company Calendar

Last Earnings: 3/23/2023
Today: 6/07/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HOWL
CUSIP: N/A
CIK: 1785530
Web: werewolftx.com
Phone: 617-952-0555
Fax: N/A
Employees: 46
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.10
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $8.30
Forecasted Upside/Downside: +228.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,810,000.00
Net Margins: -241.79%
Pretax Margin: -241.79%
Return on Equity: -40.02%
Return on Assets: -28.70%

Debt

Debt-to-Equity Ratio: 0.32
Current Ratio: 7.21
Quick Ratio: 7.21

Sales & Book Value

Annual Sales: $16.40 million
Price / Sales: 7.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.98 per share
Price / Book: 0.85

Miscellaneous

Outstanding Shares: 35,610,000
Free Float: 13,283,000
Market Cap: $120.36 million
Optionable: Not Optionable
Beta: 0.20

Key Executives

Dr. Daniel J. Hicklin Ph.D. (Age 59)
Founder, CEO, Pres, Sec. & Director
Comp: $817.31k

Dr. Cynthia Seidel-Dugan Ph.D. (Age 64)
Chief Scientific Officer
Comp: $600.35k

Dr. Randi Isaacs M.D. (Age 67)
Chief Medical Officer
Comp: $637.15k

Mr. Timothy W. Trost CPA (Age 65)
CFO, Treasurer & Assistant Sec.

Dr. Reid Leonard Ph.D. (Age 64)
Chief Operating Officer

Dr. Chulani Karunatilake Ph.D. (Age 64)
Chief Technology Officer

Ms. Ellen A. Lubman M.B.A. (Age 47)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HOWL Stock - Frequently Asked Questions

Should I buy or sell Werewolf Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings or view top-rated stocks.
What is Werewolf Therapeutics' stock price forecast for 2023?: 2 brokers have issued 1 year target prices for Werewolf Therapeutics' shares. Their HOWL share price forecasts range from $8.30 to $15.00. On average, they predict the company's stock price to reach $11.10 in the next twelve months. This suggests a possible upside of 228.4% from the stock's current price.
View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts.
How have HOWL shares performed in 2023?: Werewolf Therapeutics' stock was trading at $2.05 on January 1st, 2023. Since then, HOWL stock has increased by 64.9% and is now trading at $3.38.
View the best growth stocks for 2023 here.
When is Werewolf Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our HOWL earnings forecast.
How were Werewolf Therapeutics' earnings last quarter?: Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its earnings results on Thursday, March, 23rd. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.20. The firm had revenue of $7.28 million for the quarter, compared to analyst estimates of $3.15 million. Werewolf Therapeutics had a negative net margin of 241.79% and a negative trailing twelve-month return on equity of 40.02%.
When did Werewolf Therapeutics IPO?: (HOWL) raised $101 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Werewolf Therapeutics' stock symbol?: Werewolf Therapeutics trades on the NASDAQ under the ticker symbol "HOWL."
Who are Werewolf Therapeutics' major shareholders?: Werewolf Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rubric Capital Management LP (5.45%), Alyeska Investment Group L.P. (1.12%), Acadian Asset Management LLC (0.22%), Schonfeld Strategic Advisors LLC (0.21%), HBK Sorce Advisory LLC (0.15%) and State Street Corp (0.14%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends.
How do I buy shares of Werewolf Therapeutics?: Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Werewolf Therapeutics' stock price today?: One share of HOWL stock can currently be purchased for approximately $3.38.
How much money does Werewolf Therapeutics make?: Werewolf Therapeutics (NASDAQ:HOWL) has a market capitalization of $120.36 million and generates $16.40 million in revenue each year. The company earns $-53,810,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.
How can I contact Werewolf Therapeutics?: Werewolf Therapeutics' mailing address is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. The official website for the company is werewolftx.com. The company can be reached via phone at 617-952-0555 or via email at ir@werewolftx.com.

This page (NASDAQ:HOWL) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial